Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

RVC collaborates with UCB on bone overgrowth research
"It is an incredible opportunity to advance our understanding of this ultra-rare bone disease" - Dr Tim Dreyer.

The project will explore Sclerosteosis and Ankylosing Spondylitis.

The Royal Veterinary College (RVC) is collaborating with the biopharmaceutical company UCB to research diseases of excessive bone formation.

In a new multi-year research project, the organisations will investigate therapeutic options and mechanisms of disease progression in two severe bone diseases characterised by bone overgrowth - sclerosteosis, and the inflammatory condition ankylosing spondylitis.

Dr Scott Roberts, senior lecturer in translational skeletal research at the RVC, said: “I am excited to be working closely with UCB and RVC colleagues to investigate why pathological bone is formed in ankylosing spondylitis and how excessive bone formation can be controlled in sclerosteosis. 

“This research interaction will allow us to further our understanding of these specific diseases, with our accrued knowledge also likely to be applicable to other conditions of altered bone metabolism.”

Sclerosteosis is an ultra-rare genetic bone disease, in which patients experience widespread bone overgrowth as a result of the loss of sclerostin expression. The overgrowth of bone can result in severe, and even fatal, pressure on the brain due to increases in skull thickness. This can only be resolved temporarily through major surgery.

Ankylosing spondylitis patients also experience bone overgrowth, occurring most commonly in the spine. This overgrowth can lead to pain, bone fusion and deformity. The major change of structural tissue damage can result in permanent disability. 

Over the course of three years, the team of researchers led by Dr Scott Roberts, will test potential new therapeutic options in preclinical models for sclerosteosis. Whilst ankylosing spondylitis already has approved therapeutics, the team will be researching why this bone forms using specialised disease models via human stem cells. 

Dr Tim Dreyer, postdoctoral researcher and sclerosteosis patient, commented on the new collaboration: “As a patient myself, I am thrilled to be part of a collaboration that aims to potentially develop a therapeutic for Sclerosteosis. 

“It is an incredible opportunity to advance our understanding of this ultra-rare bone disease, whilst providing hope for a small group of patients and their families.”

Senior vice president and head of discovery science at UCB, Dr Alistair Henry, added: “We are delighted to partner with the RVC on this important project to better understand disease progression in these two conditions. 

“Although very different diseases, both conditions have a painful and progressive impact on those living with them and we hope this project may pave the way for treatment to improve people’s lives.”

 

Image (C) Royal Veterinary College

Become a member or log in to add this story to your CPD history

Practices urged to audit neutering data

News Story 1
 RCVS Knowledge has called on vet practices to audit their post-operative neutering outcomes.

It follows the release of the 2024 NASAN benchmarking report, which collates data from neutering procedures performed on dogs, cats and rabbits.

The benchmarking report enables practices in the UK and Ireland to compare their post-operative outcomes to the national average. This includes the rate of patients lost to follow-up, which in 2024 increased to 23 per cent.

Anyone from the practice can submit the data using a free template. The deadline for next report is February 2026.

Visit the RCVS Knowledge website to complete an audit. 

Click here for more...
News Shorts
New guidance for antibiotic use in rabbits

New best practice guidance on the responsible use of antibiotics in rabbits has been published by the BSAVA in collaboration with the Rabbit Welfare Association & Fund (RWA&F).

The guidance is free and has been produced to help veterinary practitioners select the most appropriate antibiotic for rabbits. It covers active substance, dose and route of administration all of which are crucial factors when treating rabbits owing to the risk of enterotoxaemia.

For more information and to access the guide, visit the BSAVALibrary.